{
    "clinical_study": {
        "@rank": "46835", 
        "arm_group": [
            {
                "arm_group_label": "Japanese Healthy volunteers", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Caucasian Healthy volunteers", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This open-label, parallel group study will evaluate the safety, tolerability,\n      pharmacokinetics and pharmacodynamics of single doses of inclacumab in Japanese healthy\n      volunteers compared to Caucasian healthy volunteers. Subjects will receive a single\n      intravenous dose of inclacumab. Follow-up will be for up to 197 days."
        }, 
        "brief_title": "A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female volunteers, 18 to 55 years of age, inclusive Healthy status\n             as defined by absence of evidence of any active or chronic disease following a\n             detailed medical and surgical history and a complete physical examination\n\n          -  Japanese subjects must have Japanese parents and grandparents who were born in Japan\n\n          -  Caucasian subjects must have Caucasian parents and grandparents\n\n          -  Body mass index (BMI) 18 - 30 kg/m2 inclusive\n\n        Exclusion Criteria:\n\n          -  Clinically significant abnormalities in laboratory test results (including positive\n             test for HIV, hepatitis B and/or C), vital signs or ECGs\n\n          -  Any confirmed significant allergic reactions against any drug, or multiple allergies\n             (non-active hay fever is acceptable)\n\n          -  Smokes more than 5 cigarettes per day during the three months prior to study conduct\n\n          -  Participation in an investigational drug or device study within 30 days or 5\n             half-lives prior to screening\n\n          -  Positive test for drugs of abuse\n\n          -  Any suspicion of or history of alcohol and/or other substance abuse or addiction\n\n          -  Pregnant or lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "62", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01815827", 
            "org_study_id": "BP28134"
        }, 
        "intervention": {
            "arm_group_label": [
                "Japanese Healthy volunteers", 
                "Caucasian Healthy volunteers"
            ], 
            "description": "single intravenous doses", 
            "intervention_name": "inclacumab", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Anaheim", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92801"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "up to 197 days"
            }, 
            {
                "measure": "Pharmacokinetics: Maximum plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "up to 197 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01815827"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacodynamics: Blood platelet leukocytes aggregation (PLA)", 
                "safety_issue": "No", 
                "time_frame": "up to 197 days"
            }, 
            {
                "measure": "Pharmacodynamics: Plasma (free and total) soluble P-selectin", 
                "safety_issue": "No", 
                "time_frame": "up to 197 days"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 10 months"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}